Amylyx officer plans 22,807-share tax sale

Officer Camille L. Bedrosian filed a Rule 144 notice for an automatic sale of Amylyx shares to cover taxes on vesting performance stock units.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. (AMLX) received a Rule 144 notice for a planned sale of common stock for the account of officer Camille L. Bedrosian. The sale relates to the vesting of performance-based restricted stock units on September 10, 2026, covering 22,807 shares to satisfy tax withholding obligations, with sales described as automatic and not at the officer’s discretion.

Key Figures

Shares related to vesting: 22,807 shares Date of Notice: September 11, 2026 Issuer phone: 617-682-0917

3 metrics

Shares related to vesting 22,807 shares Common stock tied to vesting of performance-based restricted stock units on September 10, 2026

Date of Notice September 11, 2026 Date the Rule 144 notice for Amylyx Pharmaceuticals, Inc. was filed

Issuer phone 617-682-0917 Contact phone number for Amylyx Pharmaceuticals, Inc.

Key Terms

Rule 144, performance-based Restricted Stock Units, tax withholding obligations, automatic

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

performance-based Restricted Stock Units financial

"Vesting of Performance-based Restricted Stock Units"

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

tax withholding obligations financial

"shares required to be sold ... to cover tax withholding obligations"

automatic other

"Such sales were automatic and not at the discretion of the Reporting Person."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Rule 144 filing disclose for AMLX?

It discloses that Camille L. Bedrosian, an officer of Amylyx Pharmaceuticals, Inc., filed a Rule 144 notice to sell shares related to vesting performance-based restricted stock units on September 10, 2026, primarily to cover tax withholding obligations.

How many AMLX shares are tied to the vesting event in this filing?

The filing states that 22,807 shares of Amylyx common stock are associated with the vesting of performance-based restricted stock units on September 10, 2026, with shares to be sold to satisfy tax withholding obligations.

Why is Camille L. Bedrosian selling AMLX shares under Rule 144?

The sale represents shares required to be sold to cover tax withholding obligations tied to the vesting of performance stock units. The filing notes that these sales were automatic and not at the discretion of the reporting person.

When was the Rule 144 notice for AMLX filed?

The Date of Notice in the Rule 144 filing is September 11, 2026, following the September 10, 2026 vesting of performance-based restricted stock units that triggered the related share sale for tax withholding.

Which broker is involved in the planned AMLX share sale?

The broker listed for the common stock in the Rule 144 filing is Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY 10004, in connection with potential sales of Amylyx common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:02 PM Accepted by SEC EDGAR 09/11/2026 - 04:01 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001326969
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Amylyx Pharmaceuticals, Inc.
SEC File Number	001-41199
Address of Issuer	55 Cambridge Parkway Suite 6W Cambridge MASSACHUSETTS 02142
Phone	617-682-0917
Name of Person for Whose Account the Securities are To Be Sold	Bedrosian Camille L
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC 1 New York Plaza 8th Floor New York NY 10004	10028	324868	278064	09/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/10/2026	Vesting of Performance-based Restricted Stock Units	Issuer			22807	09/10/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	This sale represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Date of Notice	09/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua B. Cohen, as Attorney in Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)